Adverse events with botulinum toxin treatment in cervical dystonia: How much should we blame placebo?

Parkinsonism and Related Disorders

Volumn 56, Issue , 2018, Pages 16-19

  Duarte, Gonçalo S ^a,b   Rodrigues, Filipe B ^a,b,c   Ferreira, Joaquim J ^a,b,d   Costa, João ^a,b  

^a INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^b INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d CNS Campus Neurológico Senior   (Portugal)

Author keywords

Adverse events; Botulinum toxin; Cervical dystonia; Meta analysis; Placebo effect

Indexed keywords

BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; PLACEBO; ANTIPARKINSON AGENT; MUSCLE RELAXANT AGENT;

CALCULATION; CERVICAL DYSTONIA; DRUG EFFICACY; DRUG RESPONSE; DYSPHAGIA; HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SHORT SURVEY; SYSTEMATIC REVIEW; TREATMENT OUTCOME; WEAKNESS; XEROSTOMIA; MUSCLE WEAKNESS; PLACEBO EFFECT; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); TORTICOLLIS;

ANTI-DYSKINESIA AGENTS; BOTULINUM TOXINS, TYPE A; DEGLUTITION DISORDERS; HUMANS; MUSCLE WEAKNESS; NEUROMUSCULAR AGENTS; PLACEBO EFFECT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TORTICOLLIS; TREATMENT OUTCOME;

EID: 85048552249     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2018.06.017     Document Type: Short Survey

References (15)

1. Castelão, M., Marques, R.E., Duarte, G.S., Rodrigues, F.B., Ferreira, J., Sampaio, C., Moore, A.P., Costa, J., Botulinum toxin type A therapy for cervical dystonia. Cochrane Database Syst. Rev., 12, 2017.
2. Marques, R.E., Duarte, G.S., Rodrigues, F.B., Castelão, M., Ferreira, J., Sampaio, C., Moore, A.P., Costa, J., Botulinum toxin type B for cervical dystonia. Cochrane Database Syst. Rev., 5, 2016.
3. Duarte, G.S., Castelão, M., Rodrigues, F.B., Marques, R.E., Ferreira, J., Sampaio, C., Moore, A.P., Costa, J., Botulinum toxin type A versus botulinum toxin type B for cervical dystonia. Cochrane Database Syst. Rev., 10, 2016.
4. Govindarajan, R., Shepard, K.M., Moschonas, C., Chen, J.J., Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache Payment policy perspectives. Neurology: Clin. Pract. 6:3 (2016), 281–286.
5. Albanese, A., Asmus, F., Bhatia, K., Elia, A.E., Elibol, B., Filippini, G., Gasser, T., Krauss, J., Nardocci, N., Newton, A., EFNS guidelines on diagnosis and treatment of primary dystonias. Eur. J. Neurol. 18:1 (2011), 5–18.
6. Simpson, D.M., Hallett, M., Ashman, E.J., Comella, C.L., Green, M.W., Gronseth, G.S., Armstrong, M.J., Gloss, D., Potrebic, S., Jankovic, J., Practice guideline update summary: botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache report of the guideline development subcommittee of the american academy of neurology. Neurology 86:19 (2016), 1818–1826.
7. Silva, M.A., Duarte, G.S., Camara, R., Rodrigues, F.B., Fernandes, R.M., Abreu, D., Mestre, T., Costa, J., Trenkwalder, C., Ferreira, J.J., Placebo and nocebo responses in restless legs syndrome: a systematic review and meta-analysis. Neurology, 88(23), 2017.
8. Team, R.C., R: a Language and Environment for Statistical Computing. 2017, R Foundation for Statistical Computing, Vienna, Austria.
9. Higgins, J.P.T., Thompson, S.G., Deeks, J.J., Altman, D.G., Measuring inconsistency in meta-analyses. BMJ Br. Med. J. (Clin. Res. Ed.) 327:7414 (2003), 557–560.
10. Barron, A.J., Zaman, N., Cole, G.D., Wensel, R., Okonko, D.O., Francis, D.P., Systematic review of genuine versus spurious side-effects of beta-blockers in heart failure using placebo control: recommendations for patient information. Int. J. Cardiol. 168:4 (2013), 3572–3579.
11. Finegold, J.A., Manisty, C.H., Goldacre, B., Barron, A.J., Francis, D.P., What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomized placebo-controlled trials to aid individual patient choice. European Journal of Preventive Cardiology 21:4 (2014), 464–474.
12. Hróbjartsson, A., Gøtzsche, P.C., Placebo Interventions for all Clinical Conditions. 2010, The Cochrane Library.
13. McCambridge, J., Witton, J., Elbourne, D.R., Systematic review of the Hawthorne effect: new concepts are needed to study research participation effects. J. Clin. Epidemiol. 67:3 (2014), 267–277.
14. Hill, F., Miller, N., Walsh, R.A., Mockler, D., McDowell, R., Walshe, M., Botulinum toxin for drooling in Parkinson's disease. Cochrane Database Syst. Rev., 10, 2016.
15. Consky ES, B.A., Belle, L., Ranawaya, R., Lang, A.E., The Toronto western spasmodic Torticollis rating scale (TWSTRS): assessment of validity and inter-rater reliability. Neurology, 40, 1990, 445.